PMN-310 is under clinical development by ProMIS Neurosciences and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMN-310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PMN-310 overview

PMN-310 is under development for the treatment of Alzheimer’s disease. The drug candidate is developed based on the proprietary discovery platform, consisting of ProMIS and collective coordinates, to successfully identify distinct target epitopes on prion-like strains of misfolded amyloid beta (amyloid precursor protein). It is administered through intravenous route.

ProMIS Neurosciences overview

ProMIS Neurosciences (ProMIS), formerly Amorfix Life Sciences is a development stage biopharmaceutical company that focuses on the development of therapeutic antibodies and diagnostics for the treatment of neurodegenerative disorders. The companies major products include tests functional assays. The company’s PMN 310, a monoclonal antibody (mAb), designated as its first lead product for development in AD. It uses ProMIS technology, helps in predicting new disease-specific epitopes on the molecular surface of misfolded proteins. Based on ProMIS technology, the company is developing antibody therapeutics and diagnostics targeting Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease. ProMIS is headquartered in Toronto, Ontario, Canada.

For a complete picture of PMN-310’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.